> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Branch-duct IPMN without worrisome features has raised pancreatic cancer incidence
- URL: https://www.coios.me/branch-duct-ipmn-without-worrisome-features-has-raised/
- Published: 2026-11-18T13:00:18.000Z
- Updated: 2026-11-18T14:04:23.000Z
- Description: In 1,234 Japanese patients with low-risk branch-duct IPMN, concomitant pancreatic ductal adenocarcinoma arose at 4.91 times the expected rate.
- Author: Daniel Ryan
- Tags: Health today, Cancer, Japan, #peer-reviewed, #refines, #item, #source-2026-11, #score-60

A prospective multicentre Japan Pancreas Society registry followed 1,234 patients with branch-duct IPMN lacking worrisome features or high-risk stigmata. Over up to 5.17 years of 6-monthly surveillance, 26 developed advanced neoplasia, a cumulative incidence of 2.48%. Ten had high-grade dysplasia or invasive IPMN, and 16 had concomitant pancreatic ductal adenocarcinoma (cPDAC). Standardised incidence ratios against the general population were 3.07 and 4.91 respectively, and 8.01 overall. Diabetes history and mural nodules predicted high-grade dysplasia or invasive IPMN; raised CA19-9 and new or worsening diabetes predicted cPDAC. The effect of longer, guideline-recommended surveillance intervals was simulated rather than observed.

*Why it is interesting: These cysts are considered low-risk, yet those under 20 mm showed a higher cPDAC ratio than larger ones. Simulated guideline-recommended longer intervals delayed detection of advanced neoplasia in 13 of 19 eligible patients.*

Source

[Annals of Surgery, 17 November 2026](https://doi.org/10.1097/sla.0000000000007255?ref=coios.me)

DOI

10.1097/sla.0000000000007255

Type

Peer-reviewed article

Design

Prospective multicentre Japan Pancreas Society registry cohort, n=1234 branch-duct IPMN without worrisome features, 6-monthly imaging, follow-up to 5.17 years; cumulative incidence, SIRs, competing-risk analysis with simulated extended intervals

Verdict

Refines prior evidence

Driver

[Cancer](https://www.coios.me/d-cancer/)